Outcomes

The available evidence for Pancragen (Lys-Glu-Asp-Trp-NH2 tetrapeptide) comes exclusively from preclinical studies in laboratory animals, with no clinical trial data in humans. The reported outcomes are limited and the strength of evidence is weak.

Glucose Metabolism:

Studies in aged female rhesus monkeys reported correction of impaired glucose tolerance and impacts on pancreatic endocrine function (2014-2015)
One rat study with experimental diabetes mellitus showed effects on blood glucose levels (2007)

Pancreatic Cell Function:

Multiple studies (2010-2013) reported effects on pancreatic cell differentiation and functional activity during aging in laboratory models
Claims of tissue-specific stimulation of cell differentiation during aging (2012)

Other Reported Effects:

In diabetic rats, effects on capillary permeability and adhesion were noted alongside glucose changes (2007)

Evidence Limitations:
The evidence base is notably limited. All studies appear to be from the same research group, published primarily in Russian journals between 2007-2015. No peer-reviewed clinical trials in humans were identified. The specific methodologies, sample sizes, statistical analyses, and magnitude of reported effects are not detailed in the available abstracts. Without access to full study protocols and results, the clinical significance of these findings cannot be properly evaluated.

Disclaimer: This information is for educational purposes only and should not be used for medical decision-making. Consult healthcare professionals for medical advice regarding any therapeutic interventions.

Pancragen

Member access required